Gilead Sciences Reports $6.78 EPS for 2025, Beating Street Estimates
Gilead Sciences (NASDAQ: GILD) reported full-year 2025 earnings per share of $6.78, capping off a strong year with net income reaching $8.51 billion, according to the company's latest SEC filing released February 10, 2026.
Key Numbers
The biopharmaceutical giant's 2025 performance showcased solid execution across its portfolio. Full-year earnings per share came in at $6.78, reflecting the company's ability to maintain profitability despite ongoing challenges in the pharmaceutical industry. Net income for the full year totaled $8.51 billion, demonstrating Gilead's continued cash generation capabilities.
Quarterly performance throughout 2025 showed consistency, with third-quarter earnings reaching $5.04 per share on net income of $6.33 billion. The company maintained steady profitability across all reported quarters, with Q2 2025 delivering $2.61 per share and net income of $3.27 billion.
Revenue figures from recent periods indicate the company's substantial market presence. Historical data shows fiscal 2020 revenue of $24.69 billion, with quarterly revenues ranging from $6.58 billion to $17.27 billion during that period. These figures underscore Gilead's position as a major player in the biopharmaceutical sector.
The company's financial results reflect both GAAP and non-GAAP measures, with management emphasizing that non-GAAP information provides additional context for internal operating and financial planning purposes. The reconciliation between GAAP and non-GAAP figures is detailed in the company's press release accompanying the 8-K filing.
What Management Said
While specific management commentary was not included in the preliminary 8-K filing, the company's decision to report both GAAP and non-GAAP financial measures suggests management's focus on providing transparency around operational performance. The filing indicates that management uses non-GAAP information internally for operating, budgeting, and financial planning purposes, signaling a commitment to providing investors with the same lens through which the company evaluates its own performance.
The timing of the earnings release, coming in early February for the year ended December 31, 2025, demonstrates management's commitment to timely financial reporting. The company filed the results with the SEC on February 10, 2026, the same day as the announcement, indicating efficient financial reporting processes.
Chief Financial Officer Andrew D. Dickinson signed the filing, representing the company's executive leadership in certifying the accuracy of the reported financial information.
What to Watch
Several factors merit attention as investors digest Gilead's latest financial results. The company's ability to generate substantial earnings and maintain strong profitability positions it well for continued investment in research and development, crucial for a biopharmaceutical company's long-term success.
The consistency in quarterly earnings throughout 2025 suggests stable operational performance, though investors will want to monitor whether this trend continues into 2026. With net income exceeding $8.5 billion for the full year, Gilead maintains significant financial flexibility for strategic initiatives, potential acquisitions, or returning capital to shareholders.
The company's focus on providing both GAAP and non-GAAP metrics indicates management's awareness of the importance of operational metrics beyond standard accounting measures. Investors should pay attention to these reconciliations in future quarters to understand the underlying business performance.
Gilead's position in the competitive biopharmaceutical landscape remains solid based on these financial results. The company's ability to generate significant cash flow provides resources for pipeline development and potential strategic moves in an industry where innovation and acquisition often drive growth.
Looking ahead, key areas to monitor include the company's product pipeline progress, particularly in its core therapeutic areas, and how management deploys its substantial cash generation capabilities. The pharmaceutical industry faces ongoing challenges including pricing pressures, regulatory scrutiny, and the need for continuous innovation, making Gilead's strong financial foundation particularly valuable.
The company's next earnings report will provide additional color on business momentum heading into 2026, including any updates on strategic priorities and capital allocation plans. With solid 2025 results now reported, attention turns to whether Gilead can maintain this performance level while advancing its therapeutic pipeline.
*Source: Gilead Sciences Form 8-K filed with the SEC on February 10, 2026*
*StockCliff Research*